BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 10831274)

  • 1. Preoperative UFT administration for patients with advanced colorectal cancer--increased uptake of 5-fluorouracil by tumor tissue is a prognostic factor.
    Nakagoe T; Ishikawa H; Sawai T; Tsuji T; Ayabe H; Eida K; Nogawa T; Nakamura Y; Kunisaki T; Tobinaga K; Furukawa M; Ino M
    Anticancer Drugs; 2000 Mar; 11(3):155-63. PubMed ID: 10831274
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Results of pharmacokinetic modulating chemotherapy in combination with hepatic arterial 5-fluorouracil infusion and oral UFT after resection of hepatic colorectal metastases.
    Kusunoki M; Yanagi H; Noda M; Yoshikawa R; Yamamura T
    Cancer; 2000 Sep; 89(6):1228-35. PubMed ID: 11002217
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A cost comparison of oral tegafur plus uracil/folinic acid and parenteral fluorouracil for colorectal cancer in Canada.
    Maroun J; Asche C; Romeyer F; Mukherjee J; Cripps C; Oza A; Skillings J; Letarte J
    Pharmacoeconomics; 2003; 21(14):1039-51. PubMed ID: 13129416
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A pharmacological study of the weekday-on/weekend-off oral UFT schedule in colorectal cancer patients.
    Sadahiro S; Suzuki T; Kameya T; Iwase H; Tajima T; Makuuchi H
    Cancer Chemother Pharmacol; 2001 May; 47(5):457-60. PubMed ID: 11391863
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of 5-fluorouracil pharmacokinetics in patients receiving continuous 5-fluorouracil infusion and oral uracil plus N1-(2'-tetrahydrofuryl)-5-fluorouracil.
    Ho DH; Pazdur R; Covington W; Brown N; Huo YY; Lassere Y; Kuritani J
    Clin Cancer Res; 1998 Sep; 4(9):2085-8. PubMed ID: 9748123
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An anticancer drug sensitivity test to determine the effectiveness of UFT as postoperative adjuvant chemotherapy for patients with stage III colorectal cancer.
    Isogai A; Nagaya M; Matsuoka H; Watanabe T; Tsukikawa S; Kubota S
    Surgery; 2007 Nov; 142(5):741-8. PubMed ID: 17981195
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Patient preference and pharmacokinetics of oral modulated UFT versus intravenous fluorouracil and leucovorin: a randomised crossover trial in advanced colorectal cancer.
    Borner MM; Schoffski P; de Wit R; Caponigro F; Comella G; Sulkes A; Greim G; Peters GJ; van der Born K; Wanders J; de Boer RF; Martin C; Fumoleau P
    Eur J Cancer; 2002 Feb; 38(3):349-58. PubMed ID: 11818199
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multicenter phase III study of uracil/tegafur and oral leucovorin versus fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer.
    Douillard JY; Hoff PM; Skillings JR; Eisenberg P; Davidson N; Harper P; Vincent MD; Lembersky BC; Thompson S; Maniero A; Benner SE
    J Clin Oncol; 2002 Sep; 20(17):3605-16. PubMed ID: 12202661
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Concentrations of 5-fluorouracil (5-FU) in serum and tissues at venous injection of tegafur or 5-FU--clinical study on colorectal cancer].
    Kojima T; Suzumura K; Kanemitsu T; Miyashita A; Inamura Y; Owa Y; Naruse T
    Gan To Kagaku Ryoho; 1998 Mar; 25(4):547-51. PubMed ID: 9530361
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Randomised phase III trial of adjuvant chemotherapy with oral uracil and tegafur plus leucovorin versus intravenous fluorouracil and levofolinate in patients with stage III colorectal cancer who have undergone Japanese D2/D3 lymph node dissection: final results of JCOG0205.
    Shimada Y; Hamaguchi T; Mizusawa J; Saito N; Kanemitsu Y; Takiguchi N; Ohue M; Kato T; Takii Y; Sato T; Tomita N; Yamaguchi S; Akaike M; Mishima H; Kubo Y; Nakamura K; Fukuda H; Moriya Y
    Eur J Cancer; 2014 Sep; 50(13):2231-40. PubMed ID: 24958736
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Using preoperative UFT to predict sensitivity to fluoropyrimidines in colorectal cancer.
    Fujii M
    Oncology (Williston Park); 1999 Jul; 13(7 Suppl 3):55-60. PubMed ID: 10442363
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dual antitumor effects of 5-fluorouracil on the cell cycle in colorectal carcinoma cells: a novel target mechanism concept for pharmacokinetic modulating chemotherapy.
    Yoshikawa R; Kusunoki M; Yanagi H; Noda M; Furuyama JI; Yamamura T; Hashimoto-Tamaoki T
    Cancer Res; 2001 Feb; 61(3):1029-37. PubMed ID: 11221829
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Pre- and post-operative adjuvant chemotherapy of colorectal cancer. Part 1. Drug concentration in tissues following UFT administration].
    Tomita M; Shimoyama T; Hirano T; Nakagoe T; Shimizu T; Kusano H; Fukuda Y; Eida K; Ishii T; Kotake Y
    Gan To Kagaku Ryoho; 1988 Dec; 15(12):3239-43. PubMed ID: 3143310
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of bolus injection of 5-fluorouracil on steady-state plasma concentrations of 5-fluorouracil in Japanese patients with advanced colorectal cancer.
    Tamura T; Kuwahara A; Kadoyama K; Yamamori M; Nishiguchi K; Inokuma T; Takemoto Y; Chayahara N; Okuno T; Miki I; Fujishima Y; Sakaeda T
    Int J Med Sci; 2011; 8(5):406-12. PubMed ID: 21750645
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic value of 5-fluorouracil metabolic enzyme genes in Dukes' stage B and C colorectal cancer patients treated with oral 5-fluorouracil-based adjuvant chemotherapy.
    Yamada H; Iinuma H; Watanabe T
    Oncol Rep; 2008 Mar; 19(3):729-35. PubMed ID: 18288408
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [5-FU pharmacokinetic study of 5-FU hepato-arterial infusion with oral UFT].
    Maruyama M; Ebuchi M; Nagahama T; Takashima I; Hasegawa K; Ochiai T; Natui S
    Gan To Kagaku Ryoho; 2002 Nov; 29(12):2109-11. PubMed ID: 12484014
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The efficacy of oral tegafur-uracil as maintenance therapy following intravenous 5-fluorouracil chemotherapy in stage III colon cancer.
    Hong KD; Lee SI; Moon HY
    Hepatogastroenterology; 2012; 59(113):104-7. PubMed ID: 22251527
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antitumor activity and low intestinal toxicity of S-1, a new formulation of oral tegafur, in experimental tumor models in rats.
    Takechi T; Nakano K; Uchida J; Mita A; Toko K; Takeda S; Unemi N; Shirasaka T
    Cancer Chemother Pharmacol; 1997; 39(3):205-11. PubMed ID: 8996521
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A novel weekday-on/weekend-off UFT schedule.
    Sadahiro S; Makuuchi H; Suzuki T; Tokunaga N; Ishizu K; Tajima T
    Oncology (Williston Park); 2000 Oct; 14(10 Suppl 9):87-90. PubMed ID: 11098503
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tegafur and 5-fluorouracil pelvic tissue concentrations in rectal cancer patients receiving preoperative chemoradiation.
    Calvo FA; Aldaz A; Zufía L; de la Mata D; Serrano J; García R; Arranz JA; Alvarado A; Giráldez J
    Clin Transl Oncol; 2006 Jul; 8(7):500-7. PubMed ID: 16870540
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.